Cargando…

Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?

OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Otto, Wolfgang, Burger, Maximilian, Fritsche, Hans-Martin, Blana, Andreas, Roessler, Wolfgang, Knuechel, Ruth, Wieland, Wolf F., Denzinger, Stefan
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872595/
https://www.ncbi.nlm.nih.gov/pubmed/20689609
_version_ 1782181236328890368
author Otto, Wolfgang
Burger, Maximilian
Fritsche, Hans-Martin
Blana, Andreas
Roessler, Wolfgang
Knuechel, Ruth
Wieland, Wolf F.
Denzinger, Stefan
author_facet Otto, Wolfgang
Burger, Maximilian
Fritsche, Hans-Martin
Blana, Andreas
Roessler, Wolfgang
Knuechel, Ruth
Wieland, Wolf F.
Denzinger, Stefan
author_sort Otto, Wolfgang
collection PubMed
description OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. MATERIAL AND METHODS: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence. RESULTS: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively. CONCLUSIONS: PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.
format Text
id pubmed-2872595
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-28725952010-05-27 Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? Otto, Wolfgang Burger, Maximilian Fritsche, Hans-Martin Blana, Andreas Roessler, Wolfgang Knuechel, Ruth Wieland, Wolf F. Denzinger, Stefan Clin Med Oncol Original Research OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. MATERIAL AND METHODS: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence. RESULTS: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively. CONCLUSIONS: PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups. Libertas Academica 2009-04-30 /pmc/articles/PMC2872595/ /pubmed/20689609 Text en © 2009 by the authors http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Original Research
Otto, Wolfgang
Burger, Maximilian
Fritsche, Hans-Martin
Blana, Andreas
Roessler, Wolfgang
Knuechel, Ruth
Wieland, Wolf F.
Denzinger, Stefan
Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title_full Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title_fullStr Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title_full_unstemmed Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title_short Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
title_sort photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872595/
https://www.ncbi.nlm.nih.gov/pubmed/20689609
work_keys_str_mv AT ottowolfgang photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT burgermaximilian photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT fritschehansmartin photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT blanaandreas photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT roesslerwolfgang photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT knuechelruth photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT wielandwolff photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults
AT denzingerstefan photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults